Shots:

• The EMA's CHMP has issued a positive opinion recommending the marketing authorization for regdanvimab (CT-P59) in adults with COVID-19 who do not require supplemental oxygen & are at increased risk of progressing to severe COVID-19
• The CHMP opinion was based on the P-III clinical trial to evaluate the efficacy and safety of regdanvimab in 1315+ patients with COVID-19 across 13 countries including the US, Spain & Romania. The results showed a 72% reduction in the risk of COVID-19 related hospitalization or death in high-risk patients
• The company has recently reported the development of a neutralizing Ab cocktail in combination with CT-P59 against new emerging variants of SARS-CoV-2

 Ref: Businesswire | Image:Celltrion